Developmental encephalopathies and epileptic encephalopathies – diagnosis and options for modern treatment of Dravet syndrome and Lennox – Gastaut syndrome
DOI:
https://doi.org/10.5281/zenodo.16882835Keywords:
Developmental encephalopathies, Epileptic encephalopathies, antiseizure medications, Dravet syndrome, Lennox-Gastaut syndrome, cannabidiol, fenfluramineAbstract
Epileptic encephalopathies are defined as drug-resistant epilepsies in which seizures and/or EEG discharges impair neuropsychiatric development and cognitive functions. Developmental encephalopathies occur with delayed neuropsychiatric development or intellectual deficit, caused by non-progressive brain damage, combined or not with epilepsy, in which the neurocognitive and behavioral deficit remains, regardless of the control of epilepsy. A new concept for developmental encephalopathies and epileptic encephalopathies is that epilepsy and developmental delay are two conditions with a common etiology (structural or genetic causes) in which aggressive antiepileptic treatment is necessary. Epileptic encephalopathies are defined as a process of neurological damage caused by epileptic activity with variable potential for treatment. Epileptic activity affects neurogenesis, synaptogenesis, the normal organization of neuronal networks, triggers neuroinflammation, with possible pathophysiological mechanisms for neuronal damage. According to the age of onset, epileptic encephalopathies are: early infantile (Otahara syndrome, syndrome with epileptic infantile spasms or West syndrome, migratory focal seizures, Dravet syndrome) and late ( Lennox – G astaut s yndrome, e pileptic e ncephalopathies with sharp – slow wave activation in sleep, Landau Kleffner syndrome, atypical benign focal epilepsy of childhood, hemiconvulsion-hemiplegia syndrome, epileptic syndrome associated with febrile infections); With onset at different ages are epileptic syndromes with progressive neurological damage, Rasmussen syndrome, progressive myoclonic epilepsy, Febrile-infectious associated epileptic syndromes. In them, continuous epileptic activity or frequent epileptic seizures cause cognitive regression.
Neurocognitive and behavioral abnormalities can improve with control of epileptic seizures and reduction of interictal epileptic activity. Timely diagnosis of epileptic encephalopathies with knowledge of their main clinical characteristics, especially Lennox – Gastaut syndrome and Dravet syndrome and their early treatment improves their prognosis. Therapeutic approaches for the treatment of epileptic encephalopathies are monotherapy and subsequent rational polytherapy including new anticonvulsant drugs (AEDs). Information is presented on the diagnosis, clinical characteristics and modern treatment of Lennox – Gastaut syndrome and Dravet syndrome.
References
Александрова, И., Божинова, В, Димова, П. Електричен статус по време на сън- етиология, клинични форми и прогноза (I чaст). Българска неврология, 2014, 15, 1, 11-15. [Aleksandrova, I., Bojinova, V., Dimova, P. Electrichen status po vreme na san – etiologiya, klinichni formi I prognoza (I chast). Balgarska nevrologia, 15, 1, 11-15] https://www.nevrologiabg.com/journal/index.php/neurology/issue/view/53
Александрова, И., Божинова, В. Натриеви каналопатии и епилепсия (I част). Българска неврология. 2021, 22, 3, 86-92. [Aleksandrova, I., Bojinova, V. Natrievi kanalopatii i epilepsiya (I chast), Balgarska nevrologia, 2021, 22, 3, 86-92] https://www.nevrologiabg.com/journal/index.php/neurology/article/view/90
Александрова, И., Божинова, В. Натриеви каналопатии и епилепсия (II част). Българска неврология. 2021, 22, 3, 92-97. [Aleksandrova, I., Bojinova, V. Natrievi kanalopatii i epilepsiya (II chast), Balgarska nevrologia, 2021, 22, 3, 92-97] https://www.nevrologiabg.com/journal/index.php/neurology/article/view/91
Божинова, В., Александрова И., Стоянова, В. Детска церебрална парализа, епилепсия и интелектуален дефицит- етиология, диагностика и терапия. Педиатрия, 2014, 54, 2, 35-41. [Bojinova, V., Aleksandrova, I., Stoyanova, V. Detska cerebralna paraliza, epilepsiya i intelektualen deficit – etiologiya, diagnostika i terapia. Pediatriya, 2014, 54, 2, 35-41]
Белопитова, Л., Божинова В., Йотова, Р. Синдром на Lennox-Gastaut-клинична еволюция и прогноза. Педиатрия. 2002, 42, 1, 22-25. [Belopitova, L., Bojinova, V., Jotova, R. Sindrom na Lennox-Gastaut – klinichna evoljucia I prognoza. Pediatriya, 2002, 42, 1, 22-25]
Димова, П., Тодоров, Т., Киров, А., Александрова, И., Божинова В., Тодорова, А. Молекулярно-генетично проучване на гените CDКL5 и PCRH19 при тежки епилепсии у момичета. Българска неврология. 2013, 14, 143-147. [Molekulyarnogenetichni prouchvaniya na genite CDKL5 I PCRH19 pri tejki epilepsii u momicheta, Balgarska nevrologia, 2013, 14, 143-147] https://www.nevrologiabg.com/journal/index.php/neurology/issue/view/51
Миланов, И., Божинова, В. Национален консенсус за диагностика и лечение на епилепсията. Българска неврология, 2023, 24, 6, 1-38. [Milanov, I., Bojinova, V., Nacionalen consensus za diagnostika i lechenie na epilepsiyata. Balgarska nevrologia, 2023, 24, 6, 1-38] https://www.nevrologiabg.com/journal/index.php/neurology/issue/view/114
Миланов, И., Божинова, В. Фармакотерапевтично ръководство за лечение на неврологичните заболявания, 2024, „Стено“, Варна, 867 с. [Milanov, I., Bojinova, V. Farmakoterapevtichno rakovodstvo za lechenie na nevrologichni zabolyavaniya, 2024, “Steno”, Varna, 876.]
Absalom, N.L., Liao, V.W.Y., Kothur, K., Indurthi, D.C., Bennetts, B., Troedson, C., Mohammad, S.S., Gupta, S., McGregor, I.S., Bowen, M.T., Lederer, D., Mary, S., De Waele, L., Jansen, K., Gill, D., Kurian, M.A., McTague, A., Møller, R.S., Ahring, P.K., Dale, R.C., Chebib, M. Gain-of-function and loss-offunction GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Nat Commun, 2022, 13, 1822.
Aleksandrova, I., Asenova, A., Dimova, P., Deneva, D., Rodopska, E., Slavkova, E., Bojinova, V. Electrical Status Epilepticus during Sleep: Risk Factors, Clinical Course, and Treatment Approaches. J Child Sci. 2023, 13, e40–e46.
Arzimanoglou, A., French, J., Blume, W.T., Cross, J.H., Ernst, J.P., Feucht, M., Genton, P., Guerrini, R., Kluger, G., Pellock, J.M., Perucca, E., Wheless, J.W. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol, 2009, 8, 1, 82-93.
Asadi-Pooya, A. Lennox-Gastaut syndrome: a comprehensive review Neurological Sciences. 2018, 39, 3, 403–414.
Azmanov, D., Zhelyazkova, S., Dimova, P., Radionova, M., Bojinova, V., Tournev, I., Jablensky, A., Mulley, J., Scheffer, J., Kalaydjieva, L., Sander, J.W. Mosaicism of a missense SCN1A mutation and Dravet syndrome in a Roma/Gypsy family. Epileptic Disorders. 2010, 12, 117-124.
Bagdy, G., Riba, P., Jakus, R. Serotonin and epilepsy. J Neurochem 2007, 100, 857–873.
Bahi-Buisson, N., Villeneuve, N., Caietta, E., Jacquette, A., Maurey, H., Matthijs, G., Van Esch, H., Delahaye, A., Moncla, A., Milh, M., Zufferey, F., Diebold,1 B., Bienvenu, T. Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships. Am J Med Genet, Part A. 2012, 158A, 1612–1619.
Berkovic, S.F. Epileptic encephalopathies of infancy: welcome advances. Lancet, 2019, 394, 10216, 2203–2204.
Bonardi, C.M., Heyne, H.O., Fiannacca, M. et al. KCNT1- related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum. Brain, 2021, 144, 3635–3650.
Brunklaus, A., Ellis, R., Reavey, E., Zuberi, S.M. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain, 2012, 135, 2329–2336.
Chang, Y.T., Hong, S.Y., Lin, W.D., Lin, C.H., Lin S.S., Tsai, F.J., Chou, I.C. Genetic Testing in Children with Developmental and Epileptic Encephalopathies: A Review of Advances in Epilepsy Genomics. Children (Basel), 2023, 10, 3, 556.
Ciranna, L. Serotonin as a modulator of glutamate- and GABAmediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol, 2006, 4, 2, 101-114.
Cross, J.H., Auvin, S., Falip, M., Striano, P., Arzimanoglou, A. Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations. Front Neurol, 2017, 8, 505.
Devinsky, O., Cross, J.H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I.E., Thiele, E.A., Wright, S. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med, 2017, 376, 2011-2020.
Devinsky, O., Patel, A.D., Cross, J.H., Villanueva, V. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. New England Journal of Medicine, 2018, 378, 20, 1888-1897.
Ding, J., Li, X., Tian, H., Wang, L., Guo, B., Wang, Y., Li, W., Wang, F., Sun, T. SCN1A Mutation-Beyond Dravet Syndrome: A Systematic Review and Narrative Synthesis. Front Neurol, 2021, 12, 743726.
Guerrini, R., Conti, V., M, antegazza, M., Balestrini, S., Galanopoulou, A.S., Benfenati, F. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. Physiol Rev, 2023, 103, 1, 433-513.
Jiang, X., Raju, P.K., D‘Avanzo, N., Lachance, M., Pepin, J., Dubeau, F., Mitchell, W.G., Bello-Espinosa, L.E., Pierson, T.M., Minassian, B.A., Lacaille, J.C., Rossignol, E. Both gainoffunction and loss-of-function de novo CACNA1A mutations cause severe developmental epileptic encephalopathies in the spectrum of Lennox-Gastaut syndrome. Epilepsia, 2019, 60, 9, 1881-1894.
Johannesen, K.M., Liu, Y., Koko, M., Gjerulfsen, C.E., Sonnenberg, L. et al. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications. Brain, 2022, 145, 9, 2991-3009.
Kalser, J., Cross, J.H. The epileptic encephalopathy jungle – from Dr West to the concepts of aetiology-related and developmental encephalopathies. Curr Opin Neurol, 2018, 31, 2, 216-222.
Knupp, K.G., Scheffer, I.E., Ceulemans, B., Sullivan, J.E., Nickels, K.C., Lagae, L., Guerrini, R., Zuberi, S.M., Nabbout, R., Riney, K., Shore, S., Agarwal, A., Lock, M., Farfel, G.M., Galer, B.S., Gammaitoni, A.R., Davis, R., Gil-Nagel, A. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome A randomised controlled trial. JAMA Neurol, 2022, 79, 554–564.
Lagae, L., Brambilla, I., Mingorance, A., Gibson, E., Battersby, A. Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey. Dev Med Child Neurol, 2018, 60, 1, 63-72.
Lagae, L., Sullivan, J., Knupp, K., Laux, L., Polster, T., Nikanorova, M., Devinsky, O., Cross, J.H., Guerrini, R., Talwar, D., Miller, I., Farfel, G., Galer, B.S., Gammaitoni, A., Mistry, A., Morrison, G., Lock, M., Agarwal, A., Lai, W.W., Ceulemans, B.; FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet, 2019, 394, 10216, 2243-2254.
Martin, P., de Witte, P.A.M., Maurice, T., Gammaitoni, A., Farfel, G., Galer, B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav, 2020, 105, 106989.
Moller, R. S. Wuttke, T.V., Helbig, I., Marini, C., Johannesen, K.M., Brilstra, E.H., Vaher, U., Borggraefe, I., Talvik, I., Talvik, T., Kluger, G., Francois, L.L., Lesca, G., de Bellescize, J., Blichfeldt, S., Chatron, N., Holert, N., Jacobs, J., Swinkels, M., Betzler, C., Syrbe, S., Nikanorova, M., Myers, C.T., Larsen, L.H., Vejzovic, S., Pendziwiat, M., von Spiczak, S., Hopkins, S., Dubbs, H., Mang, Y., Mukhin, K., Holthausen, H., van Gassen, K.L., Dahl, H.A., Tommerup, N., Mefford, H.C., Rubboli, G., Guerrini, R., Lemke, J.R., Lerche, H., Muhle, H., Maljevic, S. Mutations in GABRB3: From febrile seizures to epileptic enc ephalopathies. Neurology, 2017, 88, 483–492.
Mulkey, S.B., Ben-Zeev, B., Nicolai, J., Carroll, J.L., Grønborg, S., Jiang, Y.H., Joshi, N., Kelly, M., Koolen, D.A., Mikati, M.A., Park, K., Pearl, P.L., Scheffer, I.E., Spillmann, R.C., Taglialatela, M., Vieker, S., Weckhuysen, S., Cooper, E.C., Cilio, M.R. Neonatal nonepileptic myoclonus is a prominent clinical feature of KCNQ2 gain-of-function variants R201C and R201H. Epilepsia, 2017, 58, 3, 436-445
Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S; FAiRE, DS Study Group. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. JAMA Neurol. 2020, 77, 3, 300-308.
Peycheva, V., Ivanova, N., Kamenarova, K., Tsekova, I., Aleksandrova, I., Bozhinova, V., Bozhidarova, M., Litvinenko, I., Hristova, D., Mitev, V., Kaneva, R., Jordanova, A. Impact of KCNQ2 mutations in Bulgarian patients with electroclinical syndromes with onset in the first year of life. Biotechnology & Biotechnological Equipment, 2017, 31, 1, 138-142.
Peycheva, V., Ivanova, N., Kamenarova, K., Panova, M., Pacheva, I., Ivanov, I., Bojidarova, M., Tacheva, G., Stamatov, D., Litvinenko, I., Hristova, D., Deneva, D., Rodopska, E., Slavkova, E., Aleksandrova, I., Simeonov, E., Dimova, P., Bojinova, V., Mitev, V., Jordanova, A., Kaneva, R. SCN1A mutation spectrum in a cohort of Bulgarian patients with GEFS+ phenotype The Turkish Journal of Pediatrics, 2020, 62, 711-725.
Riney, K., Bogacz, A., Somerville, E., Hirsch, E., Nabbout, R., Scheffer, I.E., Zuberi, S.M., Alsaadi, T., Jain, S., French, J., Specchio, N., Trinka, E., Wiebe, S., Auvin, S., Cabral-Lim, L., Naidoo, A., Perucca, E., Moshé, S.L., Wirrell, E.C., Tinuper, P. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 6, 1443-1474.
Riva, A., Coppola, A., Di Bonaventura, C., Ferlazzo, E., Gobbi, G., Marini, C., Meletti, S., Romeo, A., Santoro, K., Verrotti, A., Capovilla, G., Striano, P.; Italian LGS Delphi Group. An Italian consensus on the management of Lennox-Gastaut syndrome. Seizure, 2022, 101, 134-140.
Ryskamp, D.A., Korban, S., Zhemkov, V., Kraskovskaya, N., Bezprozvanny, I. Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases. Front Neurosci, 2019, 13, 862.
Scheffer, I.E., Berkovic, S., Capovilla, G., Connolly, M.B., French, J., Guilhoto, L., Hirsch, E., Jain, S., Mathern, G.W., Moshé, S.L., Nordli, D.R., Perucca, E., Tomson, T., Wiebe, S., Zhang, Y.H., Zuberi, S.M. ILAE classification of the epilepsies: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58, 512–521.
Shorvon, S.D., Guerrini, R., Cook, M, eds. Oxford textbook of epilepsy and epileptic seizures. Oxford: Oxford Univ. Press. 2013, p. 13.
Sourbron, J., Smolders, I., de Witte, P., Lagae, L. Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in SCN1A Mutant Zebrafish. Front Pharmacol, 2017, 8, 191- 204.
Specchio, N., Curatolo, P. Developmental and epileptic encephalopathies: what we do and do not know. Brain, 2021, 144, 1, 32-43.
Specchio, N., Wirrell, E.C., Scheffer, I.E., Nabbout, R., Riney, K., Samia, P., Guerreiro, M., Gwer, S., Zuberi, S.M., Wilmshurst, J.M., Yozawitz, E., Pressler, R., Hirsch, E., Wiebe, S., Cross, H.J., Perucca, E., Moshé, S.L., Tinuper, P., Auvin, S. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 6, 1398-1442.
Stamberger, H., Nikanorova, M., Willemsen, M.H. Accorsi, P., Angriman, M., Baier, H., Benkel-Herrenbrueck, I., Benoit, V., Budetta, M., Caliebe, A., Cantalupo, G., Capovilla, G., Casara, G., Courage, C., Deprez, M., Destrée, A., Dilena, R., Erasmus, C.E., Fannemel, M., Fjær, R., Giordano, L., Helbig, K.L., Heyne, H.O., Klepper, J., Kluger, G.J., Lederer, D., Lodi, M., Maier, O., Merkenschlager, A., Michelberger, N., Minetti, C., Muhle, H., Phalin, J., Ramsey, K., Romeo, A., Schallner, J., Schanze, I., Shinawi, M., Sleegers, K., Sterbova, K., Syrbe, S., Traverso, M., Tzschach, A., Uldall, P., Van Coster, R., Verhelst, H., Viri, M., Winter, S., Wolff, M., Zenker, M., Zoccante, L., De Jonghe, P., Helbig, I., Striano, P., Lemke, J.R., Møller, R.S., Weckhuysen, S. STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy. Neurology. 2016, 86, 954–962.
Syrbe, S. Developmental and epileptic encephalopathies – therapeutic consequences of genetic testing. Med Genet, 2022, 34, 3, 215-224.
Syrbe, S., Hedrich, U.B.S., Riesch, E., Djémié, T., Müller, S., Møller, R.S., Maher, B., Hernandez-Hernandez, L., Synofzik, M., Caglayan, H.S., Arslan, M., Serratosa, J.M., Nothnagel, M., May, P., Krause, R., Löffler, H., Detert, K., Dorn, T., Vogt, H., Krämer, G., Schöls, L., Mullis, P.E., Linnankivi, T., Lehesjoki, A.E., Sterbova, K., Craiu, D.C., Hoffman-Zacharska, D., Korff, C.M., Weber, Y.G., Steinlin, M., Gallati, S., Bertsche, A., Bernhard, M.K., Merkenschlager, A., Kiess, W.; EuroEPINOMICS RES consortium; Gonzalez, M., Züchner, S., Palotie, A., Suls, A., De Jonghe, P., Helbig, I., Biskup, S., Wolff, M., Maljevic, S., Schüle, R., Sisodiya, S.M., Weckhuysen, S., Lerche, H., Lemke, J.R. De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nat Genet, 2015, 47, 4, 393-399.
Thiele, E.A., Marsh, E.D., French, J.A., Mazurkiewicz-Beldzinska, M., Benbadis, S.R., Joshi, C., Lyons, P.D., Taylor, A., Roberts, C., Sommerville, K.; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2018, 391, 10125, 1085-1096.
Weckhuysen, S., Ivanovic, V., Hendrickx, R., Van Coster, R., Hjalgrim, H., Møller, R.S., Grønborg, S., Schoonjans, A.S., Ceulemans, B., Heavin, S.B., Eltze, C., Horvath, R., Casara, G., Pisano, T., Giordano, L., Rostasy, K., Haberlandt, E., Albrecht, B., Bevot, A., Benkel, I., Syrbe, S., Sheidley, B., Guerrini, R., Poduri, A., Lemke, J.R., Mandelstam, S., Scheffer, I., Angriman, M., Striano, P., Marini, C., Suls, A., De Jonghe, P., KCNQ2 Study Group. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology, 2013, 81, 1697–1703.
Wolff, M., Johannesen, K.M., Hedrich, U.B.S. Masnada, S., Rubboli, G., Gardella, E., Lesca, G., Ville, D., Milh, M., Villard, L., Afenjar, A., Chantot-Bastaraud, S., Mignot, C., Lardennois, C., Nava, C., Schwarz, N., Gérard, M., Perrin, L., Doummar, D., Auvin, S., Miranda, M.J., Hempel, M., Brilstra, E., Knoers, N., Verbeek, N., van Kempen, M., Braun, K.P., Mancini, G., Biskup, S., Hörtnagel, K., Döcker, M., Bast, T., Loddenkemper, T., Wong- Kisiel, L., Baumeister, F.M., Fazeli, W., Striano, P., Dilena, R., Fontana, E., Zara, F., Kurlemann, G., Klepper, J., Thoene, J.G., Arndt. D.H., Deconinck, N., Schmitt-Mechelke, T., Maier, O., Muhle, H., Wical, B., Finetti, C., Brückner, R., Pietz, J., Golla, G., Jillella, D., Linnet, K.M., Charles, P., Moog, U., Õiglane-Shlik, E., Mantovani, J.F., Park, K., Deprez, M., Lederer, D., Mary, S., Scalais, E., Selim, L., Van Coster, R., Lagae, L., Nikanorova, M., Hjalgrim, H., Korenke, G.C., Trivisano, M., Specchio, N., Ceulemans, B., Dorn, T., Helbig, K.L., Hardies, K., Stamberger, H., de Jonghe, P., Weckhuysen, S., Lemke, J.R., Krägeloh-Mann, I., Helbig, I., Kluger, G., Lerche, H., Møller, R.S. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain, 2017, 140, 1316–1336.
Zuberi, S.M., Wirrell, E., Yozawitz, E., Wilmshurst, J.M., Specchio, N., Riney, K., Pressler, R., Auvin, S., Samia, P., Hirsch, E., Galicchio, S., Triki, C., Snead, O.C., Wiebe, S., Cross, J.H., Tinuper, P., Scheffer, I.E., Perucca, E., Moshé, S.L., Nabbout, R. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 6,1349-1397.
